<DOC>
	<DOCNO>NCT01381016</DOCNO>
	<brief_summary>The sole purpose study evaluate pathophysiology disease . The disease state evaluate obesity-related alteration reproductive hormone - The obesity epidemic United States advance accelerated pace . It estimate 2015 , 41 % U.S. adult obese define body mass index ( BMI ) great 30 kg/m2 . The U.S. government 's 2010 Dietary Guidelines regard obesity single great health hazard century . Female adult obesity associate menstrual cycle irregularity , ovulatory dysfunction high risk obstetrical complication . This reproductive phenotype obesity worsen increase BMI solely due anovulatory infertility . While association adiposity subfertility well document population study , underlie mechanism remain poorly understood . The main objective proposal clarify nature obesity-related reproductive endocrine abnormality identify potential etiology amenable therapy . - Hypothesis : The hypothalamic-pituitary axis abnormally sensitive estradiol negative feedback obesity .</brief_summary>
	<brief_title>Estrogen Sensitivity Ovulatory Dysfunction Obesity</brief_title>
	<detailed_description>- Design : paired assessment Pre Post estrogen administration obese normal weight woman - AIM 1 : To test pituitary hypothalamic responsiveness obesity , examine luteinizing hormone ( LH ) follicle-stimulating hormone ( FSH ) pulsatility frequent blood sampling . - AIM 2 : To test ovarian responsiveness obesity , examine urinary reproductive hormone ( E1c , estrone conjugate , Pdg , pregnanediol glucuronide ) entire menstrual cycle . - AIM 3 : To test hypothesis central adiposity associate reproductive hormone alteration obesity , quantitatively assess body composition dual energy x-ray absorptiometry ( DXA ) .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Age 1842 study entry Regular menstrual cycle every 2540 day BMI 18 25 kg/m2 â‰¥30kg/m2 Good general health Prolactin thyroidstimulating hormone ( TSH ) within normal laboratory range screen Baseline hemoglobin &gt; 11 gm/dl . Positive screen Activated Protein C resistance Any contraindication exogenous estrogen , include previous thromboembolic event stroke , history estrogendependent tumor , active liver disease , undiagnosed abnormal uterine bleeding , hypertriglyceridemia , smoking , hypertension History chronic disease affect hormone production , metabolism clearance ( include diabetes mellitus ) abnormal renal liver function screening , elevate aspartate alanine aminotransferase elevate blood urea nitrogen ( BUN ) creatinine Current use thiazolidinediones metformin ( know interact reproductive hormone ) Use hormone affect hypothalamicpituitary ovarian axis within three month enrollment Strenuous exercise ( &gt; 4 hour per week ) Pregnancy , breastfeed current active attempt conceive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>LH pulsatility</keyword>
	<keyword>Obesity</keyword>
	<keyword>Reproduction</keyword>
</DOC>